# Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL

> **NCT01241786** · PHASE2 · TERMINATED · sponsor: **Hackensack Meridian Health** · enrollment: 5 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia(CLL)
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Revlimid
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT01241786
- **Lead sponsor:** Hackensack Meridian Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The study was closed early due to poor accrual
- **Last updated:** 2022-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01241786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01241786, "Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01241786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*